omniture
logo
Search
科济生物医药（上海）有限公司
Media Room

Latest News

rss

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-08-24 20:50 2614
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-08-18 20:50 1687
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Appoints Dr. Hua Jiang as Executive Director

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2022-08-02 20:50 1935
CARsgen Appoints Dr. Hua Jiang as Executive Director

CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

SHANGHAI, June 6, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2022-06-06 20:50 2725

Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2022-05-10 20:50 1671

CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Cod...

2022-04-07 23:42 2224
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2022-03-23 20:50 1494
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2022-03-23 20:50 3014
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China

SHANGHAI, March 3, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-03-03 21:50 1868

CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Sto...

2022-01-17 21:50 2129
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
12